George Kong
Overview
Explore the profile of George Kong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schrittenlocher S, Luke V, Irle H, Weliwitage J, Luke J, Kong G, et al.
Klin Monbl Augenheilkd
. 2025 Jan;
PMID: 39776404
No abstract available.
2.
Arnould L, Balsat E, Hashimoto Y, White A, Kong G, Dunn H, et al.
Br J Ophthalmol
. 2024 May;
108(12):1672-1678.
PMID: 38789132
Objective: To evaluate efficacy and safety outcomes of the Xen 45 gel stent implant over 24 months of follow-up. Methods: A retrospective analysis of prospectively collected data from the Fight...
3.
Dsilva L, McCarthy K, Lyons J, Cabigas B, Campbell N, Kong G, et al.
Expert Opin Drug Saf
. 2023 Jun;
22(10):995-1002.
PMID: 37272350
Background: Progressive multifocal leukoencephalopathy (PML), an important identified risk for natalizumab, has been described for standard interval dosing (SID; dosing interval every-4-weeks). Information on PML with natalizumab extended interval dosing...
4.
Prea S, Guymer R, Kong G, Vingrys A
J Clin Med
. 2023 Apr;
12(7).
PMID: 37048613
Background: To determine the 12-month compliance with and retention of home monitoring (HM) with Melbourne Rapid Fields (MRFh) for patients with intermediate age-related macular degeneration (iAMD) and compare visual acuity...
5.
Foley J, Campbell N, Kong G
Lancet Neurol
. 2023 Feb;
22(3):200-201.
PMID: 36804085
No abstract available.
6.
Foley J, Defer G, Zhovtis Ryerson L, Cohen J, Arnold D, Butzkueven H, et al.
Lancet Neurol
. 2022 Apr;
21(7):608-619.
PMID: 35483387
Background: Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy. Switching to extended-interval dosing...
7.
Castelnovo G, Gerlach O, Freedman M, Bergmann A, Sinay V, Castillo-Trivino T, et al.
CNS Drugs
. 2021 Jul;
35(9):1009-1022.
PMID: 34322853
Background: Prolonged-release fampridine (PR-FAM) 10-mg tablet twice daily is the only approved pharmacological treatment for improvement of walking ability in adults with multiple sclerosis (MS). LIBERATE assessed the safety/effectiveness of...
8.
Larkin J, Minor D, DAngelo S, Neyns B, Smylie M, Miller Jr W, et al.
J Clin Oncol
. 2017 Jul;
36(4):383-390.
PMID: 28671856
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point...
9.
Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han S, Thuluvath P, et al.
Ann Hepatol
. 2016 Oct;
15(6):834-845.
PMID: 27740516
Material And Methods: In this single-arm, open-label study, 246 patients received daclatasvir plus pegIFN alfa-2a and weight-based RBV. Patients with an extended rapid virologic response (eRVR; undetectable HCV-RNA at treatment...
10.
Weber J, Gibney G, Sullivan R, Sosman J, Slingluff Jr C, Lawrence D, et al.
Lancet Oncol
. 2016 Jun;
17(7):943-955.
PMID: 27269740
Background: Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events....